A single dose of psilocybin, a naturally occurring psychedelic compound found in mushrooms, has been shown to provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder. The findings come from a phase 2 trial published in Wiley Online’s CANCER journal.
Psilocybin is a chemical found in certain types of mushrooms that has been used for centuries. When ingested, psilocybin is metabolised into psilocin, which binds to serotonin receptors in the brain and alters consciousness. In the phase 2 trial, researchers found significant reductions in depression symptoms in over half of the patients, with some experiencing lasting relief.
The study involved 28 patients with cancer and major depressive disorder who received a single dose of 25 mg psilocybin combined with psychological support. The results showed that 15 patients (54%) experienced significant drops in depression symptoms, with scores improving by an average of 15 points. For anxiety symptoms, 13 patients (46%) had significant decreases, with some experiencing lasting relief.
The researchers are now conducting an ongoing trial to evaluate the effects of multiple doses of psilocybin on depression and anxiety in cancer patients. The findings suggest that psilocybin could offer a powerful new alternative to traditional antidepressants, potentially providing long-term relief from symptoms of depression and anxiety for cancer patients with major depressive disorder.
Source: https://www.openaccessgovernment.org/psychedelic-therapy-with-psilocybin-relieves-depression-in-cancer-patients/194025